Müller E E, Genazzani A R, Murru S
J Clin Endocrinol Metab. 1978 Dec;47(6):1352-7. doi: 10.1210/jcem-47-6-1352.
Nomifensine, an antidepressant agent which activates dopamine (D) neurotransmission mainly by inhibiting DA reuptake in the central nervous system, was administered either to puerperal lactating women or to subjects with nonpuerperal hyperprolactinemia. In 10 postpartum women and in 7 women with no evidence of PRL-secreting tumor, oral administration of nomifensine (100 or 200 mg, respectively) induced in the following 5 h a clear-cut inhibition of plasma PRL levels; in 10 patients with PRL-secreting tumors, the drug did not lower plasma PRL levels. In 2 of these patients nonsupressibility of plasma PRL levels to nomifensine was the only indication of the existence of a pituitary microadenoma. It is proposed that acute nomifensine testing may be a valid neuropharmacological tool for discriminating between individuals with and without pituitary adenoma.
诺米芬辛是一种主要通过抑制中枢神经系统中多巴胺（D）再摄取来激活多巴胺神经传递的抗抑郁药，被给予产后哺乳期妇女或非产后高泌乳素血症患者。在10名产后妇女和7名无泌乳素分泌瘤证据的妇女中，口服诺米芬辛（分别为100或200毫克）在接下来的5小时内导致血浆泌乳素水平明显受到抑制；在10名泌乳素分泌瘤患者中，该药物并未降低血浆泌乳素水平。在其中2名患者中，血浆泌乳素水平对诺米芬辛无抑制作用是存在垂体微腺瘤的唯一指征。有人提出，急性诺米芬辛试验可能是区分有无垂体腺瘤个体的一种有效的神经药理学工具。
